Discriminating phenotypic signatures identified for tocilizumab, adalimumab, and tofacitinib monotherapy and their combinations with methotrexate

Discriminating phenotypic signatures identified for tocilizumab, adalimumab, and tofacitinib monotherapy and their combinations with methotrexate

Abstract Background Clinical trials have shown combinations of anti–tumor necrosis factor biologicals plus methotrexate (MTX) are more effective treatments for rheumatoid arthritis than biological monotherapies, based, in part, on the assumption that MTX reduces the immunogenicity of biologicals. Ho...

Full description

Bibliographic Details
Main Authors: Alison O’Mahony, Markus R. John, Hannah Cho, Misato Hashizume, Ernest H. Choy
Format: Article
Language:English
Published: BMC 2018-06-01
Series:Journal of Translational Medicine
Subjects:
Inflammation
Biological therapy
Disease-modifying antirheumatic drugs
Rheumatoid arthritis
Ligands
Online Access:http://link.springer.com/article/10.1186/s12967-018-1532-5

Internet

http://link.springer.com/article/10.1186/s12967-018-1532-5

Similar Items